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Summary
Breast cancer (Bc) represents 25% of all malignancies in croatian women, and in 18.8% of cases, it is diagnosed before 
the age of 50. croatia launched Brca testing of people at increased family risk. Hereditary Bc is mainly caused by a patho-
genic mutation in the BRCA1 or BRCA2 gene and is a significant risk factor for developing breast and ovarian cancer.
the present study included 127 women diagnosed with Bc, with a strong family history of Bc and the known status 
of the germline mutations in the BRCA1/BRCA2 genes. the majority of women were BRCA1/2 mutation non-carriers, while 
15.7% were BRCA1/2 mutation carriers, and 4% had a variant of unknown significance (VUS). BRCA1/2 mutation carriers 
were younger than non-carriers (median 38.5 years vs. 44 years) (p=.01) and had tumors of higher histological grade (p<.001). 
The intrinsic subtype of BC differs significantly depending on the type of mutation (P<.001). Triple-negative BC prevailed 
(87.5%) in BRCA1 mutation carriers, and 12.5% had a luminal B/Her2-negative Bc. four patients were BRCA2 mutation 
carriers, and two of them had luminal B/HER2-positive BC. Most BRCA1/2 non-carriers (69.2%) and all VUs-carriers have 
luminal B/Her2-negative Bc.
our results show that BRCA1/2 mutation testing is essential for women with a family history burden. it is a piece of 
valuable information in breast cancer risk assessment and contributes to early diagnosis.
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INTRODUCTION
Breast cancer (Bc) is the most common can-
cer in women and is still one of the leading causes 
of death in the world. Twenty-five percent of all 
newly diagnosed malignancies in women were 
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breast cancers, and four percent were ovarian can-
cers in Croatia in 2017 (1). Many genetic, environ-
mental, and acquired factors are responsible for 
developing breast cancer, and early diagnosis is 
the key to successful treatment. the introduction 
of mammography screening improves early diag-
nosis and disease outcome. However, the screen-
ing does not include 18.8% of women in croatia 
diagnosed with Bc before the age of 50, including 
5% before the age of 40 (1).
Hereditary Bc is most commonly caused by 
a pathogenic mutation in the BRCA1 or BRCA2 
genes and is responsible for 5% to 10% of all breast 
cancer cases and 10% to 15% of ovarian cancer 
cases (2). the prevalence of individuals carrying 
BRCA1 or BRCA2 mutations in the general popu-
lation is estimated to be 1 in 400, with observed 
variability among populations (3,4). Mutations are 
inherited in an autosomal dominant manner and 
are highly penetrant, and as such, represent a sig-
nificant risk factor for the development of breast 
and ovarian cancer (5).
By the age of 80, the cumulative Bc risk in 
BRCA1 mutation carriers is 72% and 44% for ovar-
ian cancer, while for BRCA2 mutation carriers, 
risks are 69% for breast cancer and 17% for ovari-
an cancer (5). families with a history of breast/
ovarian cancer over several generations are pre-
disposed to developing these diseases (6). they 
have different screening schedules (earlier start 
with ultrasound and mammography, magnetic 
resonance imaging interpolation, and more fre-
quent gynecology exams)(6,7,8). Litton et al. (6) 
reported that in families affected by mutations in 
BRCA genes, breast cancer in the next generation 
develops nearly eight years earlier than in previ-
ously affected relatives. Therefore, our hospital 
has introduced genetic counseling for individuals 
with a history of breast/ovarian cancer over sev-
eral generations, according to the clinical practice 
guidelines (7,8).
We aimed to determine the proportion of 
BRCA1/2 mutation carriers in women with in-
creased familial risk who are already affected by BC 
and to compare breast cancer histological character-
istics in BRCA1/2 mutation carriers non-carriers.
PATIENTS AND METHODS
from the 1st of november 2017 until the 30th 
of May 2020, we tested 276 women with a positive 
family history for germline mutations in BRCA1 
and BRCA 2 genes, according to the genetic coun-
seling guidelines (7,8).
germline BRCA1 and BRCA2 mutations were 
analyzed in whole blood samples using next-gen-
eration sequencing on the illumina platform and 
multiplex-quantitative pcr for large rearrange-
ments. Positive results were confirmed by Sanger 
sequencing. among all women tested, 132 were 
affected by breast cancer, nine with ovarian can-
cer, and five with benign breast lesions, while 108 
women have been without the disease so far, and 
data are missing for 22 women.
the present retrospective study focused on 
breast cancer cases only. We collected complete 
data on the histological features of Bc for 127 
women from the clinical database. currently, only 
the presence or absence of mutations in the BRCA1 
and BRCA2 genes is clinically relevant, so we 
grouped statistical analysis data. Breast cancer pa-
tients with germline pathogenic mutations in any 
of the BRCA genes (BRCA1 or BRCA2) were de-
fined as BRCA1/2 mutation carriers, while patients 
without pathogenic mutations, including patients 
with a variant of unknown significance (VUS), as 
non-carriers.
We aimed to determine whether these sub-
populations significantly differ regarding breast 
cancer’s main histological characteristics: tumor 
size, histological grade, hormone receptor status, 
intrinsic molecular subtype, lymphovascular or 
perineural tumor invasion, and spread in axillary 
lymph nodes. We performed statistical analyses 
using a two-sided fisher exact test or chi-square 




figure 1 displays BRCA1/2 mutation status 
among 127 women affected with breast cancer 
(Bc), for whom we collected histopathological 
characteristics of their cancers from the clinical 
database. twenty patients (15.7%) were carriers of 
the pathogenic BRCA1/2 mutation, and most of 
the mutations (80%) were in the BRCA1 gene, 
while 107 patients were BRCA1/2 non-carriers, in-
cluding five patients (4%) with VUS.
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table 1 shows Bc’s main characteristics in 
the BRCA1/2 mutation carriers and those who are 
not carriers. the mean age at the time of Bc diag-
nosis was 44.4±10.5 years (median 43 years; range 
24-72), and 80.3% of women were younger than 50 
years. The analysis showed a significant difference 
in the age of the patients at the time of diagnosis. 
Women with BRCA1/2 mutations were younger 
than women without mutations (median 38.5 
years versus 44 years), and 60% of BRCA1/2 muta-
tion carriers were even younger than 40 years, 
compared with 29% of BRCA1/2 non-carriers 
(p=.01). also, all BRCA1/2 mutation carriers and 
67.3% of non-carriers were affected by BC before 
the age of 50. results showed that BRCA1/2 muta-
tion carriers have tumors with higher histological 
grade (p<.001) and negative estrogen receptor 
(P<.001). However, there were no differences in 
Her2 status (p=.183), positive lymph nodes 
(p=.998), or lymphovascular/perineural invasion 
(p=.183) compared to BRCA1/2 mutation non-car-
riers. approximately two-thirds of patients had 
negative axillary lymph nodes in both groups. tu-
mors did not differ significantly in size relative to 
BRCA1/2 mutation status (median size was 15.5 
mm in both groups; p=.608).
To further determine statistically significant 
differences in patient age at the time of diagnosis, 
histological grade, and status of estrogen recep-
tors, data were stratified according to the type of 
mutation. the mean age at the time of Bc diagno-
sis differed significantly according to BRCA1/2 
mutation status, as presented in figure 2. Women 
bearing BRCA1 and BRCA2 mutation were diag-
nosed before the age of 40 (38.3±7.2 and 35±4.9 
years) while women with VUs were at similar age 
at the time of diagnosis as BRCA1/2 non-carriers 
(44.6±4.1 years and 45.8±10.9 years) (p=0.008). pa-
tients with either BRCA1 or BRCA2 mutations had 
predominantly histological grade iii cancers, com-
pared with BRCA1/2 mutation non-carriers and 
VUs-carriers (p=.001) (figure 3).
overall, we recorded 19.6% of a triple-nega-
tive intrinsic subtype of breast cancer (tnBc), lu-
minal profile in 60.7% (luminal A in 15%, luminal 
B in 45.7%), luminal B/Her2-positive in 15%, and 
Her2-enriched intrinsic type (with negative hor-
mone receptors) in 4.7%.
as presented in figure 4, tnBc prevailed 
(87.5%) in BRCA1 mutation carriers, 12.5% were 
luminal B/Her2-negative, and none were Her2-
Figure 1. Germline mutation status in the BRCA1 and BRCA2 
genes among 127 breast cancer patients with a strong family 
history of breast cancer. VUS; variant of unknown significance
Table 1.
Differences in main histopathological characteristics of breast 
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* Two-sided Fisher exact test, statistically significant P-values are in bold; 
† cases with unknown parameters were excluded from the analysis
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enriched. only four patients (3.1%) were BRCA2-
mutation carriers. two of them had luminal B/
Her2-positive Bc (50%), and one each had tnBc 
and luminal a/Her2-negative.
in patients without BRCA1/2 mutations, lu-
minal/HER2-negative profile prevailed (69.2%), 
tnBc was diagnosed in only 9.8%, luminal B/
Her2-positive in 16.7%, and Her2-enriched type 
in 5.8% of cases. Besides, all five patients (4%) with 
VUS have an intrinsic luminal profile with nega-
tive Her2.
DISCUSSION
our results show that breast cancer (Bc) his-
topathological characteristics, depending on the 
status of BRCA1/2 mutations, are similar to pub-
lished data. Most women with a severe family his-
tory who are already affected by BC are BRCA1/2 
mutation non-carriers, while 15.7% of women are 
carriers of BRCA1/2 mutations. the literature re-
ported that between 12% and 25.64% of women 
with familial breast cancer are carriers of BRCA1/2 
mutations (9–13). Minor differences can be ex-
plained by the relatively small cohort in our study, 
especially given the small percentage of BRCA2 
mutations.
over 70% of women in our cohort were 
younger than 50 years. the median age at diagno-
sis was 43 years. all women with BRCA1/2 muta-
tions were diagnosed with Bc before 40, while 
women without BRCA1/2 mutations were slightly 
older (mean 45.8±10.9 years). regardless of the 
BRCA1/2 mutation status, women with hereditary 
or familial Bc become ill much earlier than the in-
cidence of sporadic Bc that occurs after age 60 
(14). this result was expected because some of the 
criteria needed for testing are the personal history 
of triple-negative breast cancer (tnBc) before age 
Figure 3. Incidence of the histological grade of breast cancer ac-
cording to BRCA1/2 mutation status (χ2=15,45; P=.001)
Figure 2. The mean age at the time of breast cancer diagnosis ac-
cording to BRCA1/2 mutation status. VUS, variant of unknown 
significance; NEG, patients without pathogenic BRCA1/2 muta-
tions (P=.008)
Figure 4. Incidence of intrinsic subtypes of breast cancer accord-
ing to BRCA1/2 mutation status (χ2=46.18; P<.001); TNBC- 
triple-negative breast cancer; Luminal profile includes both lu-
minal A and luminal B
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60 or any type of breast cancer before age 45 (7,8). 
other authors also reported a high Bc incidence 
around age 40 in BRCA1/2 mutation carriers (15–
17). the literature emphasizes that younger wom-
en have more aggressive cancer and lower surviv-
al rates. a positive family history of Bc is a very 
strong risk factor for women under 35 (relative 
risk = 3.22) (18). they reported a 39% higher risk of 
death in women affected with BC before 40. How-
ever, recent articles report a similar prognosis of 
breast cancer in BRCA1/2 mutation carriers in spo-
radic breast cancer, although there is still a dis-
agreement about this (13,19–22). a large meta-
analysis by Barreta et al. (23) showed that carriers 
of the BRCA1 mutation, but not BRCA2, have a 
higher overall survival risk than non-carriers. the 
same analysis, and a few others, reveals that the 
presence of the BRCA1/2 mutations in tnBc cor-
relates with better overall survival (13,23,24). Due 
to the known BRCA1/2 mutation-positive status, 
patients were diagnosed at an earlier stage of the 
disease, and tnBcs received adequate neoadju-
vant therapy (24). BRCA1 mutation carriers have 
enhanced sensitivity to neoadjuvant chemothera-
py with cytotoxic drugs (24). thus, those patients 
had good outcomes and more significant overall 
and disease-free survival (17,19).
BRCA1/2 mutation carriers have less differ-
entiated cancers. possibly due to a small cohort, 
we did not detect significantly larger tumors or 
more aggressive biology, e.g., with lymphovascu-
lar/perineural or lymph node invasion compared 
to non-carriers. some published results showed 
no difference in tumor size or positive lymph node 
status (12,24,25). in contrast, others recorded a sig-
nificant difference in the number of positive lymph 
nodes or lymphovascular/perineural invasion 
(9,13,17,18).
our results showed a high incidence of tnBc 
in BRCA1/2 mutation carriers, predominantly in 
BRCA1-mutation carriers (87.5%), while the aver-
age incidence in sporadic breast cancer was about 
10% (14). Her2-positive breast cancers were rare 
in BRCA1/2 mutation carriers. only two women 
who had luminal B/Her2-positive tumors had 
mutations in the BRCA2 gene, while none of the 
BRCA1 mutation carriers had a Her2-positive tu-
mor, similar to the results of Fountzilas et al. (9). 
However, most papers agree on the percentage of 
tnBc, which decreases with age at diagnosis in 
BRCA1 mutation carriers and increases with age 
in BRCA2 mutation carriers (11,12). Moreover, 
mutations in the BRCA1 gene are associated with 
a high histological grade, hormone receptor-nega-
tive, and basal gene expression profile (CK5/6- 
and cK14-positive), while mutations in the BRCA2 
gene usually shows an inverted histological pic-
ture and luminal molecular profile (16,17,22,26,27).
family history increases the risk of breast/
ovarian cancer because even in the BRCA1/2 non-
carriers group, we found almost 70% of patients 
affected by BC before the age of 50. On the other 
hand, Bc in BRCA1/2 non-carriers showed immu-
nophenotypes similar to sporadic cancers, with 
predominantly luminal features, despite family 
history. they were tnBc in less than 10%, with a 
positive estrogen receptor in over 80% of tumors 
and Her2-positive in about 20%, as previously re-
ported in sporadic cancers (14).
patients with VUs carry a change that is not 
defined as pathological so far and show character-
istics of proven BRCA1/2 non-carriers. all patients 
with VUs had only luminal/Her-negative intrin-
sic subtype with a similar age of disease as 
BRCA1/2 non-carriers. However, literature reports 
that BRCA1/2 mutation non-carriers from families 
with a strong history of Bc might harbor muta-
tions in other high- and moderate-penetrance 
genes associated with Bc risk (19,22,28).
according to the study by Brozek et al. (29), 
half of the mutation carriers lack an evident fami-
ly history and, therefore, will not be detected as 
breast-cancer families by the current selection cri-
teria. prediction algorithms for the BRCA1/2 mu-
tation carriers based on their family history can 
calculate breast and ovarian cancer risk. Based on 
probability models, women who have a 5% prob-
ability of BRCA1/2 pathogenic variant qualify for 
genetic testing, and those with 2.5% probability 
can be considered for testing (7). the nccn 
guidelines emphasize the need for multiple gene 
testing only for clinically actionable genes, as 
more information adds more complexity and dif-
ficulty to risk management decisions. When nine 
genes were tested in multi-gene panels, Yadav et 
al. (28) detected almost 30% of women with patho-
genic mutations compared to 13% of mutations 
detected when tested for BRCA1/2 genes only.
according to ruddy et al. (31), nearly 80% of 
breast cancers in young women are diagnosed as 
self-finding. There is no effective breast cancer 
screening tool for women under 40. the dense 
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breast tissue prevents routine mammography 
from being a useful screening tool. in BRCA1/2 
mutation carriers, breast cancer clinical examina-
tions should begin earlier and more frequently 
than in other women. they should also be aware 
of Bc’s warning signs, conduct regular annual ul-
trasound examinations from 25 years of age, and 
an MRI alone until 40 (7). Men with the BRCA1/2 
mutation should also have an annual clinical 
breast examination.
further monitoring of our patients will pro-
vide more information about tumor biology and 
patients’ survival factors.
CONCLUSION
our results show that testing for BRCA1/2 
mutations is essential for women who meet the 
criteria according to the guidelines and can play a 
vital role in assessing Bc risk and contribute to 
early diagnosis and possibly better treatment op-
tions.
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Sažetak
KARAKTERISTIKE RAKA DOJKE OVISNO O STATUSU MUTACIJA U GENIMA BRCA1 i BRCA2 U HrVatsKoJ
S. Ramić, G. Alfier, I. Kirac, I. Milas, P. Vuković i T. Orešić
Rak dojke predstavlja 25% svih zloćudnih bolesti u žena u Hrvatskoj, a u 18,8% slučajeva dijagnosticira se prije 50. 
godine života. Nasljedni rak dojke uglavnom je uzrokovan patogenom mutacijom u genima BRCA1 ili BRCA2 te predstav-
lja glavni čimbenik rizika za razvoj raka dojke i jajnika. Stoga je Hrvatska pokrenula testiranje mutacija u genima BRCA1 i 
BRCA2 kod osoba koje, prema smjernicama za genetičko testiranje, imaju povećani obiteljski rizik.
Ovo retrospektivno istraživanje obuhvatilo je 127 žena s pozitivnom obiteljskom anamnezom i utvrđenim statusom 
mutacija u genima BRCA1 i BRCA2, kojima je dijagnosticiran rak dojke. Većina žena nisu bile nositeljice mutacija u genima 
BRCA1 ili BRCA2 (BRCA1/2), dok je 15,7% bilo nositeljica mutacije BRCA1/2, a 4% je imalo varijantu nepoznatog značaja 
(VUS). Nositeljice mutacije BRCA1/2 bile su mlađe od ne-nositeljica (medijan 38,5 godina u odnosu na 44 godine) (P=.01) te 
su imale tumore višeg histološkog gradusa (P<.001). Intrinzični podtip raka dojke značajno se razlikuje ovisno o tipu muta-
cije (p<.001). trostruko negativni podtip raka dojke prevladao je u nositeljica mutacija u Brca1 (87,5%), a 12,5% imalo je 
luminalni B/HER2-negativni podtip. Četiri bolesnice bile su nositeljice mutacija u BRCA2 genu, od kojih dvije s luminalnim 
B/HER2-pozitivim rakom dojke. Većina bolesnica (69,2%) koje nisu nositeljice patoloških mutacija BRCA1/2 i sve one s VUS 
imale su luminalni B/Her2-negativni podtip raka dojke.
Naši rezultati pokazuju da je testiranje mutacija u genima BRCA neophodno za žene s opterećenom obiteljskom ana-
mnezom jer može igrati vitalnu ulogu u procjeni rizika od raka dojke i doprinjeti ranoj dijagnozi.
KLJUČNE RIJEČI: nasljedne mutacije, BRCA1, BRCA2, rak dojke, intrinzični podtip
